| 영문 | total lung capacity | 한글 | 전폐용량, 온허파용량 |
|---|---|---|---|
| 설명 | 폐활량(가능한 한 깊게 들여 마신 시점부터 천천히 한껏 내쉰 용량)에 잔기량(최대 날숨위치에서 폐내에 남은 용량. 약 1,200mL)을 합한 것이다. 건강한 성인은 6,000~7,000mL. 폐기종, 만성 기관지염 등의 폐색성 장애로 증가하게 되는 한편 허파섬유증, 무기폐, 흉수, 흉곽변형 등의 구속성 장애로 감소한다. |
||
| 영문 | complement | 한글 | 보체 |
|---|---|---|---|
| 설명 | 항체와 반응하여 항체와 결합된 세포의 파괴를 일으키는 단백질을 말한다. 항체가 항체와 결합한 세포를 파괴하는 방법에는 여러 가지가 있는데 그 중의 하나로 항체와 결합한 세포의 표면을 부분적으로 손상시켜 그 세포를 파괴하는 역할을 하는 것이 이 보체이다. 보체는 20가지의 단백질로 구성되어 있는데 약자로 C로 표시하며 각 종류를 나타낼 경우에는 C옆에 숫자를 써서 표시한다. |
||
| 영문 | complement fixation reaction | 한글 | 보체결합 반응, 도움체결합반응 |
|---|---|---|---|
| 설명 | 항체와의 반응에 있어서 보체와 결합하는 항체를 검사하는 방법으로, 이 반응은 최초에 기지항원, 피검혈청 및 보체를 혼합한다. 제2단계에서는 적혈구와 이것에 대응하는 용혈소의 혼합액을 가한다. 본 반응후 용혈이 일어나지 않으면 본체는 항원항체결합물에 결합한 것이 되어 양성이 되지만, 용혈이 일어난 경우 보체는 결합하지 않아 소비되지 않기 때문에 음성이 된다. 본 반응은 기지혈청을 써서 항원검출에 응용할 수 있으며, 마이코플라스마, 리케챠, 클라미디아, 바이러스, 매독 등의 진단에 쓰인다. |
||
| 영문 | hemolytic disease of newborn | 한글 | 신생아용혈병 |
|---|---|---|---|
| 설명 | 신생아에서 적혈구가 비정상적으로 많이 파괴되는 병으로 태아적모구증(erythroblastosis fetalis)와 같은 뜻으로 쓰인다. 이것은 어머니에게서 생산된 신생아나 태아의 적혈구에 대한 항체가 태반을 건너와서 태아의 적혈구와 결합하여서 생기는 용혈성빈혈을 이르는 말. 즉 신생아나 태아의 적혈구의 항체가 어머니의 몸에서 생산이 되고 이것이 태반을 통해서 태아에게 넘어가서 태아의 적혈구와 결합을 하고 이 항체와 결합한 적혈구는 파괴가 되어서 빈혈이 생긴 것을 태아적모구증이라고 한다. 이것은 Rh 적모구증(Rh erythroblastosis)와 ABO 적모구증(ABO erythroblastosis)로 나눌 수가 있다. |
||
| 영문 | hemolytic anemia | 한글 | 용혈빈혈 |
|---|---|---|---|
| 설명 | 용혈빈혈이란 적혈구의 과도한 파괴에 의한 빈혈이다. 원래 120일 정도의 수명을 가지는 적혈구의 수명이 짧아지는 것이다. 여기에는 여러 가지 원인이 있을 수가 있는데 대표적인 원인으로는 적혈구에 대한 항체가 생기는 것(발작성야간혈색소뇨증)과 적혈구자체의 이상(유전성둥근적혈구증), 그리고 다른 질병에 의해서 2차적으로 생기는 것이 있다. |
||
| AHA | acetohydroxamic acid; acquired hemolytic anemia; acute hemolytic anemia; American Heart Association;... |
|---|---|
| MHD | maintenance hemodialysis; mean hemolytic dose; mental health department; minimum hemolytic dilution;... |
| TC | target cell; taurocholate; temperature compensation; teratocarcinoma; tertiary cleavage; tetracyclin... |
| TPC | thromboplastic plasma component; thyroid papillary carcinoma; total patient care; total plasma catec... |
| TBS | total body solids; total body solute; total body surface; total burn size; Townes-Brocks syndrome; t... |
| CH 50 | Complement hemolytic activity |
|---|---|
| BHS | Beta-hemolytic streptococci |
| DHTR | Delayed hemolytic transfusion reaction |
| GABHS | Group A beta hemolytic streptococcal |
| GBS | Group B beta hemolytic streptococci |
| hemolytic anaemia | <disease, haematology> Anaemia resulting from reduced red cell survival time and haemolysis, either due to an intrinsic defect in the erythrocyte (hereditary spherocytosis or ellipsocytosis, enzyme defects, haemoglobinopathy) or an extrinsic damaging agent. For example autoantibody (autoimmune haemolytic anaemia), iso antibody, parasitic invasion of the cells (malaria), bacterial or chemical haemolysins, mechanical damage to erythrocytes. Origin: Gr. Haima = blood (18 Nov 1997) |
|---|---|
| radical mastectomy, total | Breast cancer treatment involving removal of the breast, the pectoral (chest) muscles, lymph nodes (the glands ) in the armpit and associated skin and subcutaneous tissue. (12 Dec 1998) |
| male chromosome complement | The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes). (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |
| parenteral nutrition, home total | The at-home administering of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously or by some other non-alimentary route. (12 Dec 1998) |
| parenteral nutrition, total | The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of tpn solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins. (12 Dec 1998) |
| reversal of organs, total | This condition (medically called situs inversus totalis) involves complete transposition (right to left reversal) of the thoracic and abdominal organs. The heart is not in its usual position in the left chest but is on the right. Specifically related to the heart, this is referred to as dextrocardia (literally, right-hearted). And the stomach, which is normally in the left upper abdomen, is on the right. In patients with situs inversus totalis, all of the chest and abdominal organs are reversed and appear in mirror image when examined or visualised by tests such as X-ray filming. Situs inversus totalis has been estimated to occur once in about 6-8,000 births. Situs inversus occurs in a rare abnormal condition that is present at birth (congenital) called kartagener's syndrome. (12 Dec 1998) |
| chromosome complement | The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes. (12 Dec 1998) |
| communication methods, total | Utilization of all available receptive and expressive modes for the purpose of achieving communication with the hearing impaired, such as gestures, postures, facial expression, types of voice, formal speech and non-speech systems, and simultaneous communication. (12 Dec 1998) |
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
| complement 1 | The first complement component to act in the cytolysis reaction. It is a trimolecular complex held together with ca ions and when activated, has esterase activity which initiates the next step in the sequence. (12 Dec 1998) |
| complement 1 inactivators | Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|